Aligos Therapeutics

Company snapshot

Aligos is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dys

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 32 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Aligos Therapeutics. Not investment advice.

• Peer + 0 momentum

  ENANTA PHARMACEUTICALS

  TA overlap score 36.8

• Peer + 0 momentum

  Vir Biotechnology

  TA overlap score 36.8

• Peer + 0 momentum

  Madrigal Pharmaceuticals EU

  TA overlap score 23.2

Recent activity

Latest pipeline, patent, and corporate events for Aligos Therapeutics.

1. Jun 8, 2026 Clinical update

   ALG-000184-202 — Phase 2

2. Jun 8, 2026 Clinical update

   Atorvastatin — Phase 1

3. Jun 8, 2026 Clinical update

   ALG-097558 — Phase 1

4. Jun 5, 2026 Clinical update

   ALG-055009 — Phase 1

5. May 23, 2026 Clinical update

   ALG-000184 — Phase 2

View all clinical trial activity →

• What is Aligos Therapeutics?

  Aligos Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker ALGS. Primary therapeutic focus areas include Chronic Hepatitis B, Chronic Hepatitis B Infection, Chronic Hepatitis B Virus Infection, NASH, NASH - Nonalcoholic

• Is Aligos Therapeutics publicly traded?

  Yes. Aligos Therapeutics is listed with ticker ALGS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Aligos Therapeutics develop or market?

  We link 10 drug profile(s) where Aligos Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aligos-therapeutics#company-drugs.

• What are the latest developments for Aligos Therapeutics?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Aligos Therapeutics focus on?

  Aligos Therapeutics focuses on Chronic Hepatitis B, Chronic Hepatitis B Infection, Chronic Hepatitis B Virus Infection based on our analysis of their pipeline programs and drug development activities.